Novartis: positive tone for R&D day

(CercleFinance.com) - Novartis said on Thursday that it is targeting average annual sales growth of at least 4% through to 2026, mainly driven by its top drugs.


The Swiss biopharmaceutical group said its business growth should be driven mainly by "multi-billion dollar" sales from its blockbusters.

These include Cosentyx (psoriasis), Entresto (hypertension), Kesimpta (multiple sclerosis), Zolgensma (spinal muscular atrophy), Kisqali (breast cancer) and Leqvio (cholesterol).

Novartis estimates that nearly 20 of its drugs in development have the potential to achieve sales in excess of 1 billion dollars by 2026.

These assets are expected to provide growth through 2030 and beyond, it says, by addressing medical needs for which there are no therapeutic alternatives today.

Following these statements, Novartis shares were down 0.3% on Thursday morning on the Zurich stock exchange, although this was the second best performance of the SMI index (-0.8%).



Copyright (c) 2021 CercleFinance.com. All rights reserved.